利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

84 条记录 (耗时 0.043 秒)

    Antiviral protein
    7.
    发明授权
    Antiviral protein 失效
    抗病毒蛋白

    公开(公告)号：US5340732A

    公开(公告)日：1994-08-23

    申请号：US854845

    申请日：1992-03-20

    申请人： Noriyuki Habuka ,  Masashi Miyano ,  Takashi Matsumoto ,  Masana Noma

    发明人： Noriyuki Habuka ,  Masashi Miyano ,  Takashi Matsumoto ,  Masana Noma

    IPC分类号： A61K38/00 ,  A61K47/48 ,  A61P31/12 ,  C07K14/00 ,  C07K14/415 ,  C12N1/21 ,  C12N15/09 ,  C12N15/29 ,  C12P21/02 ,  C12R1/19 ,  C12N9/12 ,  C12N15/54 ,  C12N15/70

    CPC分类号： C07K14/415 ,  A61K47/48438 ,  A61K47/48484 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/02

    摘要： An antiviral protein having an amino acid sequence represented by sequence No. 8 of a Sequence Listing is disclosed. The protein is obtained such that cysteine residues in the basic protein (MAP) obtained from Mirabilis jalapa and having antiviral activity are substituted with serine residues. More specifically, a MAP gene in which codons encoding cysteines are substituted with codons encoding serines is prepared, and this gene is integrated in a MAP secretion vector. This vector is introduced into a host to express the gene, thereby obtaining the antiviral protein. This protein retains MAP advantages as a toxic protein and has higher protein synthesis inhibition activity than that of MAP, and almost equal to that of a lysine A chain.

    摘要翻译： 公开了具有由序列表的序列号8表示的氨基酸序列的抗病毒蛋白质。 获得蛋白质，使得从Mirabilis jalapa获得并具有抗病毒活性的碱性蛋白质（MAP）中的半胱氨酸残基被丝氨酸残基取代。 更具体地，制备其中编码半胱氨酸的密码子被编码丝氨酸的密码子替代的MAP基因，并将该基因整合到MAP分泌载体中。 将该载体导入宿主以表达基因，从而获得抗病毒蛋白质。 该蛋白质保留了作为毒性蛋白质的MAP优点，并且具有比MAP更高的蛋白质合成抑制活性，并且几乎等于赖氨酸A链的蛋白质合成抑制活性。

    Recombinant human lymphotoxins that possess N-terminal extended linker peptides for antibody-binding sites
    8.
    发明授权
    Recombinant human lymphotoxins that possess N-terminal extended linker peptides for antibody-binding sites 失效
    具有抗体结合位点的N-末端延伸的接头肽的重组人淋巴毒素

    公开(公告)号：US5142026A

    公开(公告)日：1992-08-25

    申请号：US346745

    申请日：1989-05-03

    申请人： Susumu Iwasa ,  Hiroko Tada

    发明人： Susumu Iwasa ,  Hiroko Tada

    IPC分类号： A61K47/48 ,  C07K14/525 ,  C07K16/24 ,  C07K16/28

    CPC分类号： C07K14/525 ,  A61K47/48238 ,  A61K47/48423 ,  A61K47/48438 ,  C07K16/241 ,  C07K16/2881 ,  Y10S530/82

    摘要： Disclosed is a novel recombinant human lyphotoxin (LT) mutein which combines with an antibody at an inactive site of an LT molecule and liberates the LT molecule easily from the antibody after incorporation of the mutein into tumor cells.The recombinant human LT mutein is prepared by introducing a polydeoxyribonucleic acid containing a nucleotide sequence coding for the particular amino acid sequence into a replicable vector, transforming a microorganism or a cell with the recombinant DNA thus obtained, and cultivating the resulting transformant to express genetic information of the polydeoxyribonucleic acid.The recombinant human LT mutein is useful for tumor-selective carcinostatics, and effective for increasing the actively of LT and reducing the side effects thereof.

    摘要翻译： 公开了一种新型的重组人类赖克辛（LT）突变蛋白，其与LT分子的非活性位点处的抗体结合，并且在将突变蛋白掺入肿瘤细胞后，容易从抗体中释放LT分子。 通过将含有编码特定氨基酸序列的核苷酸序列的多脱氧核糖核酸引入到可复制载体中，用由此获得的重组DNA转化微生物或细胞，并培养所得转化体以表达遗传信息来制备重组人LT突变蛋白 的多脱氧核糖核酸。 重组人LT突变蛋白可用于肿瘤选择性制剂，对于增加LT的积极性和降低其副作用是有效的。

    Enzymatically active toxin coupled to a cell-specific ligand
    9.
    发明授权
    Enzymatically active toxin coupled to a cell-specific ligand 失效
    与细胞特异性配体偶联的酶活性毒素

    公开(公告)号：US5080898A

    公开(公告)日：1992-01-14

    申请号：US313599

    申请日：1989-02-21

    申请人： John R. Murphy

    发明人： John R. Murphy

    IPC分类号： A61K9/70 ,  A61K31/135 ,  A61K38/00 ,  A61K47/48 ,  C07K14/34 ,  C07K14/685 ,  C12N15/62

    CPC分类号： A61K9/7023 ,  A61K31/135 ,  A61K47/48438 ,  C07K14/34 ,  C07K14/685 ,  C12N15/62 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/33 ,  C07K2319/55 ,  C07K2319/74 ,  Y10S530/807 ,  Y10S530/81

    摘要： A cell-specific toxin molecule is prepared containing an enzymatically active toxin moiety coupled to a cell-specific binding ligand. The toxin moiety may be a diphtheria toxin, and has a non-naturally occurring cysteine residue encoded by a DNA sequence including a non-naturally occurring cysteine codon. The ligand may be a peptide hormone, proteinaceous growth factor, antibody of steroid hormone, and is derivatized with a sulfhydryl group reactive with the cysteine residue of the toxin moiety to couple the ligand to the toxin moiety via a disulfide bond. Derivatization of the ligand may be by providing the ligand with a non-naturally occurrring cysteine residue encoded by a DNA sequence including a non-naturally occurring cysteine codon. The toxin moiety exhibits cytotoxic activity but fails to exhibit generalized eukaryotic cell binding, and may be used to treat medical disorders.

    摘要翻译： 制备含有与细胞特异性结合配体偶联的酶活性毒素部分的细胞特异性毒素分子。 毒素部分可以是白喉毒素，并且具有由包含非天然存在的半胱氨酸密码子的DNA序列编码的非天然存在的半胱氨酸残基。 配体可以是肽激素，蛋白质生长因子，类固醇激素的抗体，并且用与毒素部分的半胱氨酸残基反应的巯基衍生化，以通过二硫键将配体偶联到毒素部分。 配体的衍生可以是通过向配体提供由包含非天然存在的半胱氨酸密码子的DNA序列编码的非天然存在的半胱氨酸残基。 毒素部分显示细胞毒性活性，但不能显示广泛的真核细胞结合，并且可用于治疗医学疾病。